CELLDEX THERAPEUTICS, INC.

CLDX · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Market Data

Price $40.38 +0.44 (+1.10%)

Market Cap$3.39B

P/E Ratio—

EPS$—

52W High$45.14

52W Low$20.37

Beta0.85

Data from Finnhub · Updated Aug 23, 2026